Disease · HP_0002360
Sleep disturbance
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Sleep disturbance. Diseases, record HP_0002360. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002360
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Sleep disturbance
- Open Targets ID
- HP_0002360
- Other names
- Difficulty sleeping, Sleep abnormality, Sleep disturbances, Sleep dysfunction, Sleep-wake disturbance, Trouble sleeping
- Highest stage of its drugs
- Phase 3, for 10 of its 41 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs41
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MELATONIN | CHEMBL45 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| TASIMELTEON | CHEMBL2103822 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CETIRIZINE | CHEMBL1000 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FAMOTIDINE | CHEMBL902 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GABAPENTIN ENACARBIL | CHEMBL1628502 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PRAMIPEXOLE | CHEMBL301265 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREGABALIN | CHEMBL1059 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROGESTERONE | CHEMBL103 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROTIGOTINE | CHEMBL1303 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 41
See all 41 drugsTargets90
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CACNA1A | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/773 | Drugs and targets |
| CACNA1B | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CACNA1C | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1E | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/777 | Drugs and targets |
| CACNA1F | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1G | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/8913 | Drugs and targets |
| CACNA1H | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/8912 | Drugs and targets |
| CACNA1I | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/8911 | Drugs and targets |
| CACNA1S | Voltage-gated calcium channel | 3 | Voltage-gated calcium channel modulator | Phase 3 | https://conductscience.org/library/genes/779 | Drugs and targets |
1 to 10 of 90
See all 90 targetsTrials57
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01464697 | Progesterone for Perimenopausal Night Sweats | Phase 3 | 249 | 2019-12-16 | Hot Flushes, Night Sweats | PROGESTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT00748098 | Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance | Phase 3 | 136 | 2011-05-18 | Restless Legs Syndrome, Restless Legs Syndrome (RLS) | GABAPENTIN ENACARBIL | Its record names the disease | ClinicalTrials.gov |
| NCT01906866 | Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities | Phase 3 | 125 | 2018-10-30 | Sleep Disorders | MELATONIN | Its record names the disease | ClinicalTrials.gov |
| NCT06112756 | A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause | Phase 2 | 110 | 2025-11-10 | Sleep Disturbances Associated With Menopause | ELINZANETANT | Its record names the disease | ClinicalTrials.gov |
| NCT01723904 | A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease | Phase 3 | 90 | 2014-06-03 | Advanced Parkinson's Disease | ROTIGOTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00991276 | Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance | Phase 3 | 85 | 2012-10-08 | Restless Legs Syndrome | PRAMIPEXOLE, PREGABALIN | Its record names the disease | ClinicalTrials.gov |
| NCT01628029 | Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer | Phase 2 | 68 | 2026-02-04 | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder | MELATONIN, METHYLPHENIDATE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00202449 | Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance | Not applicable | 59 | 2012-07-12 | Stress Disorders, Post-Traumatic, Sleep Disorders | PAROXETINE, PRAZOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT01355523 | The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients | Phase 2/3 | 54 | 2014-05-06 | Breast Cancer, Depression | MELATONIN | Its record names the disease | ClinicalTrials.gov |
| NCT04932096 | Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin | Phase 2 | 21 | 2025-08-20 | Traumatic Brain Injury, Critical Illness, Sleep | MELATONIN | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 57
See all 57 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| GEn 1200 mg vs Placebo: serious adverse events | 2 of 127 | 0 of 132 | 259 | NCT00748098 | Trial comparisons |
| GEn 1200 mg vs Placebo: Number of Participants Who Were Defined as Clinical Global Impression of Illness (CGI-I) Scale Responders at Week 4/10 Using LOCF | 91 of 123 | 46 of 127 | 250 | NCT00748098 | Trial comparisons |
| GEn 1200 mg vs Placebo: Number of PLMAI Responders at Week 4/10 Using LOCF | 64 of 121 | 44 of 123 | 244 | NCT00748098 | Trial comparisons |
| GEn 1200 mg vs Placebo: Number of Participants With no Self-reported Awakenings (SPSD) Due to RLS at Week 4/10 Using LOCF | 87 of 115 | 68 of 125 | 240 | NCT00748098 | Trial comparisons |
| Oral Micronized Progesterone vs Placebo Comparator: deaths from any cause | 0 of 93 | 0 of 96 | 189 | NCT01464697 | Trial comparisons |
| Oral Micronized Progesterone vs Placebo Comparator: serious adverse events | 0 of 93 | 0 of 96 | 189 | NCT01464697 | Trial comparisons |
| Oral Micronized Progesterone vs Placebo Comparator: Percentage of Women With Perceived Changes in Menstrual Flow | 65 of 90 | 74 of 86 | 176 | NCT01464697 | Trial comparisons |
| Circadin 2/5/10 mg vs Placebo: Number of Dropouts | 9 of 60 | 21 of 65 | 125 | NCT01906866 | Trial comparisons |
| BAY 3427080 / Elinzanetant vs Placebo: deaths from any cause | 0 of 55 | 0 of 55 | 110 | NCT06112756 | Trial comparisons |
| BAY 3427080 / Elinzanetant vs Placebo: serious adverse events | 0 of 55 | 2 of 55 | 110 | NCT06112756 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials36
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002360
GET https://conductscience.org/api/diseases/v1/HP_0002360/drugs?page=2